Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 6/20 | 0.86 |
| ▸ | CASP3 | P42574 | 6/20 | 0.86 |
| ▸ | CASP9 | P55211 | 6/20 | 0.86 |
| ▸ | CYCS | P99999 | 6/20 | 0.86 |
| ▸ | CCR5 | P51681 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3697511 | 0.96 | APAF1 (0.91) | APAF1CASP3CASP9CYCSCCR5 | |
| SCHEMBL3701840 | 0.95 | APAF1 (0.93) | APAF1CASP3CASP9CYCSCCR5 | |
| SCHEMBL5956047 | 0.94 | APAF1 (0.80) | APAF1CASP3CASP9CYCSCCR5 | |
| SCHEMBL3696314 | 0.93 | APAF1 (0.91) | APAF1CASP3CASP9CYCSCCR5 | |
| SCHEMBL3704146 | 0.93 | APAF1 (1.00) | APAF1CASP3CASP9CYCSCCR5 | |
| SCHEMBL3707006 | 0.92 | APAF1 (0.93) | APAF1CASP3CASP9CYCSCCR5 | |
| SCHEMBL12009685 | 0.89 | APAF1 (0.71) | APAF1CASP3CASP9CYCSACHE | |
| SCHEMBL3698065 | 0.88 | APAF1 (0.90) | APAF1CASP3CASP9CYCSCCR5 | |
| SCHEMBL3704826 | 0.88 | APAF1 (0.72) | APAF1CASP3CASP9CYCSACHE | |
| SCHEMBL3703653 | 0.87 | APAF1 (0.89) | APAF1CASP3CASP9CYCSCCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| EP-2460798-A2 | APAF-1 INHIBITOR COMPOUNDS | Laboratorios SALVAT, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | APAF1, API5, AIFM1 | APAF1 1/4885CASP3 13/4885CASP9 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.